Stay updated with breaking news from Stefan Hendriks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reuters Events Cell & Gene Therapy USA 2021 is a virtual meeting taking place on Sept. 28-29 in EST. The event will unite over 1500 stakeholders, involved in commercializing cell and gene therapies, and is free for pharma, biotech and payer organizations to attend. The program is built for senior-level execs ...
Kymriah led to responses for the majority of treated patients, with 66% achieving a complete response (CR) - News - PharmaTimes
/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
Mar 5, 2021 11:23am Novartis' Kymriah is ready for new CAR-T competition from Bristol Myers Squibb, an exec said. (Novartis) With the FDA’s recent approval for Bristol Myers Squibb’s Breyanzi, a new pharma giant is entering the CAR-T lymphoma fray. But with new, impressive real-world data and a global manufacturing expansion under its belt, rival Novartis says it's ready to rumble. Novartis last year opened CAR-T production sites in Switzerland and France, while a partner opened a facility in Japan. Another partner, Cell Therapies, has since opened the first CAR-T manufacturing site in...